SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Silence Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.58+10.90 (+125.58%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Silence Therapeutics plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Research Collaboration | – | – | $559.00K | $25.83M | $27.17M | $27.70M | $43.11M | – | – |
| Royalties | – | – | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Silence Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.